Use of rotavirus vaccines in preterm babies on the neonatal unit

Kilich, Eliz; Sadarangani, Manish

doi:10.1080/14760584.2016.1216318

Cited by 9 publications

(2 citation statements)

References 24 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 153 However, delaying vaccination until hospital discharge has its own risks, and hence opinions and guidelines on the optimal timing of vaccination is such populations differ. 154 , 155 Both HRV and HBRV were found to be safe for use in HIV-infected children with asymptomatic/mildly symptomatic disease (clinical stages I and II according to WHO classification) 156 or under antiretroviral therapy, without any evidence for vaccine virus shedding. 157–159 HBRV was also well tolerated in children with congenital or acquired intestinal disease requiring resection, administration was well tolerated.…”

Section: Discussionmentioning

confidence: 99%

Established and new rotavirus vaccines: a comprehensive review for healthcare professionals

Vetter

Gardner

Debrus

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Robust scientific evidence related to two rotavirus (RV) vaccines available worldwide demonstrates their significant impact on RV disease burden. Improving RV vaccination coverage may result in better RV disease control. To make RV vaccination accessible to all eligible children worldwide and improve vaccine effectiveness in high-mortality settings, research into new RV vaccines continues. Although current and in-development RV vaccines differ in vaccine design, their common goal is the reduction of RV disease risk in children <5 years old for whom disease burden is the most significant. Given the range of RV vaccines available, informed decision-making is essential regarding the choice of vaccine for immunization. This review aims to describe the landscape of current and new RV vaccines, providing context for the assessment of their similarities and differences. As data for new vaccines are limited, future investigations will be required to evaluate their performance/added value in a real-world setting.

show abstract

Section: Discussionmentioning

confidence: 99%

Established and new rotavirus vaccines: a comprehensive review for healthcare professionals

Vetter

Gardner

Debrus

et al. 2021

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Future vaccination strategies should also consider highrisk populations, such as preterm infants, who are at increased risk of severe RV disease, due to reduced maternal antibody levels, as placental transmission starts at 28 gestational weeks and peaks after 36 weeks [136]. Low birth-weight and severe congenital abnormalities, like cardiovascular disorders or metabolic diseases, have been identified as additional risk factors for RVGE in this highrisk category [136,137]. Vaccination practices of preterm infants vary considerably.…”

Section: Status Challenges and New Chapters To Explorementioning

confidence: 99%

Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned

Pereira

Vetter

Standaert

et al. 2020

Expert Review of Vaccines

View full text Add to dashboard Cite

Introduction: Rotavirus (RV) disease remains a prominent cause of disease burden in children <5 years of age worldwide. However, implementation of RV vaccination has led to significant reductions in RV mortality, compared to the pre-vaccination era. This review presents 15 years of real-world experience with the oral live-attenuated human RV vaccine (HRV; Rotarix). HRV is currently introduced in ≥80 national immunization programs (NIPs), as 2 doses starting from 6 weeks of age. Areas covered: The clinical development of HRV and post-marketing experience indicating the impact of HRV vaccination on RV disease was reviewed. Expert opinion: In clinical trials, HRV displayed an acceptable safety profile and efficacy against RVgastroenteritis, providing broad protection against heterotypic RV strains by reducing the consequences of severe RV disease in infants. Real-world evidence shows substantial, rapid reduction in the number of RV infections and associated hospitalizations following introduction of HRV in NIPs, regardless of economic setting. Indirect effects against RV disease are also observed, such as herd protection, decrease in nosocomial infections incidence, and a reduction of disease-related societal/ healthcare costs. However, not all countries have implemented RV vaccination. Coverage remains suboptimal and should be improved to maximize the benefits of RV vaccination.

show abstract

Neonatal Immunization

Dinleyici¹

2021

Pediatric Vaccines and Vaccinations

View full text Add to dashboard Cite

Use of rotavirus vaccines in preterm babies on the neonatal unit

Cited by 9 publications

References 24 publications

Established and new rotavirus vaccines: a comprehensive review for healthcare professionals

Established and new rotavirus vaccines: a comprehensive review for healthcare professionals

Fifteen years of experience with the oral live-attenuated human rotavirus vaccine: reflections on lessons learned

Neonatal Immunization

Contact Info

Product

Resources

About